Pharma News
ViiV Healthcare Reveals Positive Results from Phase I Trial for a Potential Longer-Acting HIV Treatment
![](https://meefro.com/wp-content/uploads/2024/03/ViiV-Healthcare-Reveals-Positive-Results-from-Phase-I-Trial-for-780x470.png)
Novel formulation of cabotegravir (CAB-ULA) allows for dosing intervals of at least four months.
Source link
#ViiV #Healthcare #Reveals #Positive #Results #Phase #Trial #Potential #LongerActing #HIV #Treatment